Rein Therapeutics prices 50 million-share follow-on offering at $1 per share
PUBT · 19h ago
Share
Listen to the news
- Rein Therapeutics priced an underwritten public offering of 50 million common shares at USD 1 per share for gross proceeds of USD 50 million.
- Underwriters received a 45-day option to buy up to 7.5 million additional shares to cover over-allotments.
- Deal expected to close May 4, 2026.
- Konik Capital Partners is sole book-running manager.
- Net proceeds earmarked to fund Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis through completion.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604302000PRIMZONEFULLFEED9711157) on May 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved